KRAS
A gene frequently mutated in cancers; long considered 'undruggable' until recent targeted therapies.
Coverage of KRAS is holding steady : 10 signals on the latest tracked day, up 67% from its three-week baseline of 6, across 3 domains (unchanged from a week ago). That makes it the #15 most-covered of the 348 concerns we track.
What’s changed
- Dietary-Derived Corchorus olitorius L. Extract Suppresses KRAS-Mutant Pancreatic Cancer by Activating Ferritinophagy-Dependent Ferroptosis. · J Food Sci · 2026-09-01
- Rare KRAS G12C mutation emerges as potential target in genitourinary cancers - Bioengineer.org · KRAS Mutation Research (Google News) · 2026-08-29
- Pancreatic Cancer Breakthrough: FDA Approves New Drug Targeting Cancer-Causing KRAS Mutations - ABP Live English · KRAS Mutation Research (Google News) · 2026-08-29
- KRAS G12C mutation identified as a rare potential target in genitourinary cancers - EurekAlert! · KRAS Mutation Research (Google News) · 2026-08-28
- DAWN-303 Trial Set to Advance INCB161734 in First-Line KRAS G12D–Mutated Metastatic Pancreatic Cancer - OncLive · KRAS Mutation Research (Google News) · 2026-08-28
- GenFleet Advances KRAS G12D Lung Cancer Drug GFH375 into First-Line Phase II Study - TipRanks · KRAS Mutation Research (Google News) · 2026-08-26
What the reporting says
It shows up alongside Colorectal Cancer (99), Lung Cancer (65 — acquisition ×3), G12d (60), Pancreatic Cancer (51), KRAS Mutant (45), KRAS G12c Mutant (18), Egfr (17 — acquisition ×2), Pdac (17).
Two steps out: ctDNA (through Colorectal Cancer, 99 shared stories on the weaker link); Immunotherapy (through Colorectal Cancer, 99 shared stories on the weaker link); Braf (through Colorectal Cancer, 69 shared stories on the weaker link); Wang (through Colorectal Cancer, 63 shared stories on the weaker link).
Tracked since Mar 11, with coverage on 136 separate days — concentrated in Oncology and Pubmed Targeted.